AbbVie (ABBV) Depreciation and Depletion (2016 - 2025)
AbbVie (ABBV) has disclosed Depreciation and Depletion for 14 consecutive years, with $203.0 million as the latest value for Q4 2025.
- On a quarterly basis, Depreciation and Depletion fell 1.46% to $203.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $762.0 million, a 0.26% change, with the full-year FY2025 number at $762.0 million, changed 0.26% from a year prior.
- Depreciation and Depletion was $203.0 million for Q4 2025 at AbbVie, up from $192.0 million in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $223.0 million in Q3 2021 to a low of $173.0 million in Q4 2021.
- A 5-year average of $193.0 million and a median of $191.5 million in 2024 define the central range for Depreciation and Depletion.
- Biggest YoY gain for Depreciation and Depletion was 79.13% in 2021; the steepest drop was 23.79% in 2021.
- AbbVie's Depreciation and Depletion stood at $173.0 million in 2021, then increased by 13.29% to $196.0 million in 2022, then decreased by 4.59% to $187.0 million in 2023, then increased by 10.16% to $206.0 million in 2024, then decreased by 1.46% to $203.0 million in 2025.
- Per Business Quant, the three most recent readings for ABBV's Depreciation and Depletion are $203.0 million (Q4 2025), $192.0 million (Q3 2025), and $186.0 million (Q2 2025).